Methods and compositions for identifying epitopes
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsStephen Elledge, Tomasz Kula, Mohammad Haj Dezfulian
Life of this patent
Estimating the term…
Abstract
Described herein are methods for identifying immune cell-specific antigens and compositions for use in the methods.
Claims23
-16. (canceled)
A molecular reporter of Granzyme B activity, comprising a fusion polypeptide comprising a GzB cleavage site (VGPD, SEQ ID NO:1) linked to a detection molecule, optionally wherein the detection molecule is an enzyme, a detectable label, an antibody-binding antigen, or an affinity tag.
(canceled)
20-23. (canceled)
A system for detection of granzyme B activity in an antigen presenting cell, comprising:
- a) a fusion polypeptide comprising a CRE recombinase functionally linked to a plasma membrane attachment peptide, wherein the CRE recombinase and membrane attachment peptide are separated by a GzB cleavage site;
- b) a reporter of CRE activity comprising a nucleic acid sequence encoding GFP and RFP in head-to-head orientation flanked by LoxP sites;
- and/or
- c) a nucleic acid sequence encoding a candidate antigen in expressible form, located proximally to a CRE activated primer recognition sequence comprising an inactive primer flanked by LoxP sites, wherein CRE induced rearrangement of the LoxP sites produces a functional primer recognition sequence.
-31. (Canceled)
A method for identifying an antigen that is recognized by a cytotoxic T cell and/or NK cell, comprising:
- a) contacting an antigen presenting cell (APC) or a library of APC of any one of with one or more cytotoxic T cells (CTLs) and/or NK cells under conditions appropriate for antigen recognition, wherein the APC comprises:
- i. an exogenous nucleic acid encoding one or more candidate antigens, wherein the one or more candidate antigens are expressed and presented with MHC class I or MHC class II molecules;
- ii. a molecular reporter of Granzyme B (GzB) activity;
- and
- iii. an exogenous inhibitor of caspase-activated deoxyribonuclease (CAD)-mediated DNA degradation, a CAD knockout, or a caspase knockout;
- b) identifying APC(s) that express recognized antigen by assaying for granzyme B activity in the APC(s), wherein increased granzyme B activity, as compared to an appropriate control, indicates the APC expresses antigen that was recognized by the cytotoxic T cell and/or NK cell;
- and
- c) isolating nucleic acid that encodes the recognized antigen from the APC identified in step b), optionally further comprising sequencing the nucleic acid isolated in step c).
(canceled)
36-46. (canceled)
Dependencies are inferred from the claim text.